In vitro, functional assays indicated that the knockdown of EBLN3P suppressed osteosarcoma cell proliferation, migration and invasion, demonstrating the potential of EBLN3P as a therapeutic target for osteosarcoma; therefore, we next investigated the underlying mechanism in osteosarcoma cell lines. The gene discussed is EBLN3P; the disease is osteosarcoma.